SCHEMBL12433142

SCHEMBL12433142

CCCOc1ccc2cc(C)ccc2c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
ALDH1A1 P00352 6/20 0.47
POLB P06746 3/20 0.47
GPR55 Q9Y2T6 1/20 0.47
L3MBTL1 Q9Y468 5/20 0.42
RAB9A P51151 3/20 0.42
ATM Q13315 2/20 0.42
HPGD P15428 6/20 0.42
CSNK2A1 P68400 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
MEN1 O00255 2/20 0.42
USP2 O75604 2/20 0.42
KMT2A Q03164 2/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
NCEH1 Q6PIU2 1/20 0.41
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13339172 0.84 ALDH1A1 (0.48) MAPTALDH1A1POLBGPR55L3MBTL1
SCHEMBL5349658 0.79 KMT2A (0.47) ALDH1A1POLBHPGDKMT2ANCEH1
SCHEMBL806512 0.78 CYP19A1 (0.52) MAPTALDH1A1POLBL3MBTL1RAB9A
SCHEMBL23271869 0.76 MAPT (0.50) MAPTALDH1A1POLBGPR55L3MBTL1
SCHEMBL12037777 0.76 MAPT (0.66) MAPTALDH1A1POLBGPR55L3MBTL1
SCHEMBL30003611 0.76 MAPT (0.50) MAPTALDH1A1POLBGPR55L3MBTL1
Ammonia Solution, Strong SCHEMBL27937794 0.76 CYP1A2 (0.49) CYP1A2CYP2A6
SCHEMBL12749053 0.76 MAPT (0.43) MAPTALDH1A1POLBGPR55L3MBTL1
SCHEMBL14376152 0.76 NCEH1 (0.52) MAPTALDH1A1POLBL3MBTL1RAB9A
SCHEMBL18644174 0.74 MAPT (0.47) MAPTALDH1A1L3MBTL1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846366-B1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-03 EP disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 US disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof SLC38A7, SLC7A1, SLC6A7 MAPT 3288/4885ALDH1A1 2442/4885POLB 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.